Desolon Special Precautions

If any signs of thromboembolic processes occur, treatment should be discontinued immediately.
Smoking increase the risk of contracting vascular diseases, a risk increasing with age. In addition, this risk is probably slightly greater in users of estrogen containing oral contraceptives than in non-users. Women over approximaterly 35 years of age should therefore be advised to stop smoking if they want to use this preparation.
In patients using estrogen-containing preparations, the risk of deep-vein thrombosis may be temporarily increased when undergoing major surgery or prolonged immobilization.
In the presence of severe varicose veins, the benefits of estrogen-containing preparations must be weighed against the possible risks.
Treatment shoud be discontinued if the results of liver function tests become abnormal.
Hepatic cell adenomas have been reported very rarely in women using oral contraceptives. The adenoma may present itself as an abdominal mass and/or with the signs and symptoms of acute abdominal pain. A bleeding hepatic cell adenoma should be considered if the patient has abdominal pain or signs of intra-abdominal bleeding.
Chloasma is occasionally seen during the use of estrogen and/or progestagen-containing preparations, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun while taking this preparation.
During the use of estrogen-containing oral contraceptives, depression may occasionally occur. If this is accompanied by a disturbance in tryptophan metabolism, administration of vitamin B6 might be therapeutic value.
The use of steroids may influence the results of certain laboratory tests.
During prolonged treatment with estrogen and/or progestagen-containing preparations periodic medical examination is advisable.
Patients with any of the following conditions should be monitored: latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions), since aggravation or recurrence may occasionally be induced during infections or anoxia, estrogen-containing preparations may induce thromboembolic processes in patients with this condition; estrogen-sensitive gynaecological disorders, egL uterine fibromyomata which may increase in size, and endometriosis which may become aggravated during estrogen treatment.